You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,807,167


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,807,167
Title:Administration of agents for the treatment of inflammation
Abstract: A method of chronically reducing a patient\'s pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.
Inventor(s): Taylor; Julie (San Francisco, CA), Yednock; Theodore A. (Forest Knolls, CA)
Assignee: Elan Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:11/540,640
Patent Claims:1. A method of chronically reducing pathological inflammation in a patient in need thereof comprising chronically administering to the patient natalizumab or an immunologically active fragment thereof that inhibits alpha-4 integrin or inhibits a dimer comprising alpha-4 integrin in a therapeutically effective amount; wherein the chronic administration is for a period of at least 6 months, the pathological inflammation is caused by multiple sclerosis, and the therapeutically effective amount is sufficient to relieve symptoms of multiple sclerosis.

2. The method of claim 1, wherein the chronic administration is for a period of at least 12 months.

3. The method of claim 1, wherein the agent is administered repeatedly in a manner to bind to alpha-4 integrin or a dimer comprising alpha-4 integrin, and wherein the administration maintains alpha-4 integrin receptor saturation at a level sufficient to chronically suppress pathological inflammation in the patient.

4. The method of claim 3, wherein the agent is administered repeatedly to the patient such that alpha-4 integrin receptor saturation is about at least 65% to about 100% in the patient.

5. The method of claim 4, wherein the saturation is at least 75%.

6. The method of claim 4, wherein the saturation is at least 80%.

7. The method of claim 1, wherein the alpha-4 integrin dimer is alpha-4 beta-1.

8. The method of claim 3, wherein the agent is administered in amount sufficient to saturate at least one alpha-4 integrin dimer receptor thereby inhibiting pathological inflammation.

9. The method of claim 8, wherein the dimer receptors are alpha-4 beta-1 or alpha-4 beta-7, and the pathological inflammation is caused by multiple sclerosis.

10. The method of claim 1, wherein natalizumab is administered by infusion every four weeks for at least 6 months in an amount of about 1 mg/kg patient to about 20 mg/kg patient.

11. The method of claim 10, wherein the infusions are administered for at least 12 months.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.